INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44m ago
HOUSE PTR4m ago
SEC 13F4m ago
ROBINHOOD CHAIN4m ago
Public company

VCYTVERACYTE, INC.

CIK 0001384101

EDGAR filingsOpen in network
Disclosed transactions58
Buys / sells2 / 32
Max Insider Score30
Connections12with evidence

VCYT · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
12
WJ
Wygant JonathanVP, Chief Accounting Officer
VCYTVERACYTE, INC.
Tax withholding
F$66K
1,306 sh
Oct 28, 2026Oct 29, 2026
traded Oct 28, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 8071 · Services-Medical Laboratories · Nov 4, 2026
  • ← Insider ofevidence
    Wygant JonathanVP, Chief Accounting Officer · Oct 29, 2026
  • ← Insider ofevidence
    Bhanji MunaDirector · Oct 20, 2026
  • ← Insider ofevidence
    Barr EliavDirector · Jun 15, 2026
9
HJ
Holstein JensDirector
VCYTVERACYTE, INC.
Option exercise · 10b5-1 plan
M
$265K
7,500 sh
Oct 27, 2026
Oct 28, 2026
traded Oct 27, 2026
+1d
SEC FORM 4

Evidence

19
HJ
Holstein JensDirector
VCYTVERACYTE, INC.
Option exercise · 10b5-1 plan
M$265K
7,500 sh
Sep 24, 2026Oct 28, 2026
traded Sep 24, 2026
+34dSEC FORM 4

Evidence

7
HJ
Holstein JensDirector
VCYTVERACYTE, INC.
Option exercise · 10b5-1 plan
M—
7,500 sh
Oct 27, 2026Oct 28, 2026
traded Oct 27, 2026
+1dSEC FORM 4

Evidence

13
HJ
Holstein JensDirector
VCYTVERACYTE, INC.
Option exercise · 10b5-1 plan
M—
7,500 sh
Sep 24, 2026Oct 28, 2026
traded Sep 24, 2026
+34dSEC FORM 4

Evidence

30
HJ
Holstein JensDirector
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$353K
7,500 sh
Sep 24, 2026Oct 28, 2026
traded Sep 24, 2026
+34dSEC FORM 4

Evidence

20
HJ
Holstein JensDirector
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$375K
7,500 sh
Oct 27, 2026Oct 28, 2026
traded Oct 27, 2026
+1dSEC FORM 4

Evidence

13
BM
Bhanji MunaDirector
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$81K
1,864 sh
Oct 19, 2026Oct 20, 2026
traded Oct 19, 2026
+1dSEC FORM 4

Evidence

9
LJ
Leite JohnGlobal Chief Commercial Off
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$161K
4,015 sh
Sep 21, 2026Sep 22, 2026
traded Sep 21, 2026
+1dSEC FORM 4

Evidence

0
CR
Chambers RebeccaChief Financial Officer
VCYTVERACYTE, INC.
Tax withholding · 10b5-1 plan
F$162K
3,603 sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

9
CR
Chambers RebeccaChief Financial Officer
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$51K
1,175 sh
Sep 4, 2026Sep 4, 2026
traded Sep 4, 2026
+0dSEC FORM 4

Evidence

8
LJ
Leite JohnGlobal Chief Commercial Off
VCYTVERACYTE, INC.
Tax withholding
F$178K
3,961 sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

0
MA
McGuire AnnieEVP, General Counsel
VCYTVERACYTE, INC.
Tax withholding · 10b5-1 plan
F$144K
3,215 sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

6
MA
McGuire AnnieEVP, General Counsel
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$92K
2,154 sh
Sep 4, 2026Sep 4, 2026
traded Sep 4, 2026
+0dSEC FORM 4

Evidence

9
CR
Chambers RebeccaChief Financial Officer
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$106K
2,477 sh
Sep 4, 2026Sep 4, 2026
traded Sep 4, 2026
+0dSEC FORM 4

Evidence

3
MA
McGuire AnnieEVP, General Counsel
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$48K
1,100 sh
Sep 4, 2026Sep 4, 2026
traded Sep 4, 2026
+0dSEC FORM 4

Evidence

20
ARK Investment Management LLC13F filer
VCYTVERACYTE, INC.
TRIM
SELL$44.51M
757.9K sh
Not disclosedAug 14, 2026quarterlySEC 13F

Evidence

17
MF
Miller Thomas F.Director
VCYTVERACYTE, INC.
Grant or award
A—
5,272 sh
Jun 11, 2026Jun 15, 2026
traded Jun 11, 2026
+4dSEC FORM 4

Evidence

13
BE
Barr EliavDirector
VCYTVERACYTE, INC.
Grant or award
A—
5,272 sh
Jun 11, 2026Jun 15, 2026
traded Jun 11, 2026
+4dSEC FORM 4

Evidence

0
CR
Chambers RebeccaChief Financial Officer
VCYTVERACYTE, INC.
Tax withholding · 10b5-1 plan
F$177K
3,693 sh
Jun 2, 2026Jun 4, 2026
traded Jun 2, 2026
+2dSEC FORM 4

Evidence

11
MA
McGuire AnnieEVP, General Counsel
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$89K
1,776 sh
Jun 4, 2026Jun 4, 2026
traded Jun 4, 2026
+0dSEC FORM 4

Evidence

14
CR
Chambers RebeccaChief Financial Officer
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$98K
1,961 sh
Jun 4, 2026Jun 4, 2026
traded Jun 4, 2026
+0dSEC FORM 4

Evidence

11
MA
McGuire AnnieEVP, General Counsel
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$69K
1,400 sh
Jun 4, 2026Jun 4, 2026
traded Jun 4, 2026
+0dSEC FORM 4

Evidence

0
MA
McGuire AnnieEVP, General Counsel
VCYTVERACYTE, INC.
Tax withholding · 10b5-1 plan
F$157K
3,292 sh
Jun 2, 2026Jun 4, 2026
traded Jun 2, 2026
+2dSEC FORM 4

Evidence

21
LJ
Leite JohnGlobal Chief Commercial Off
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$700K
14.0K sh
Jun 4, 2026Jun 4, 2026
traded Jun 4, 2026
+0dSEC FORM 4

Evidence

0
LJ
Leite JohnGlobal Chief Commercial Off
VCYTVERACYTE, INC.
Tax withholding · 10b5-1 plan
F$194K
4,059 sh
Jun 2, 2026Jun 4, 2026
traded Jun 2, 2026
+2dSEC FORM 4

Evidence

14
CR
Chambers RebeccaChief Financial Officer
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$79K
1,600 sh
Jun 4, 2026Jun 4, 2026
traded Jun 4, 2026
+0dSEC FORM 4

Evidence

1
MA
McGuire AnnieSVP, General Counsel
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$204K
5,102 sh
May 6, 2026May 8, 2026
traded May 6, 2026
+2dSEC FORM 4

Evidence

1
MA
McGuire AnnieSVP, General Counsel
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$194K
5,102 sh
May 6, 2026May 8, 2026
traded May 6, 2026
+2dSEC FORM 4

Evidence

9
HR
Haas Kevin RichardChief Dev and Tech Officer
VCYTVERACYTE, INC.
Grant or award
A—
44.2K sh
Apr 10, 2026Apr 14, 2026
traded Apr 10, 2026
+4dSEC FORM 4

Evidence

24
Gilbert Ray Cisneros, Jr.DSelf
VCYTVERACYTE, INC.
Purchase
BUY$1,001 – $15KMar 3, 2026Apr 7, 2026
traded Mar 3, 2026
+35dHOUSE PTR

Evidence

13
LJ
Leite JohnChief Commercial Officer-CLIA
VCYTVERACYTE, INC.
Grant or award
A—
36.2K sh
Mar 6, 2026Mar 10, 2026
traded Mar 6, 2026
+4dSEC FORM 4

Evidence

5
LJ
Leite JohnChief Commercial Officer-CLIA
VCYTVERACYTE, INC.
Grant or award
A—
6,578 sh
Mar 6, 2026Mar 10, 2026
traded Mar 6, 2026
+4dSEC FORM 4

Evidence

10
MA
McGuire AnnieSVP, General Counsel
VCYTVERACYTE, INC.
Grant or award
A—
32.9K sh
Mar 6, 2026Mar 10, 2026
traded Mar 6, 2026
+4dSEC FORM 4

Evidence

10
MA
McGuire AnnieSVP, General Counsel
VCYTVERACYTE, INC.
Grant or award
A—
26.3K sh
Mar 6, 2026Mar 10, 2026
traded Mar 6, 2026
+4dSEC FORM 4

Evidence

24
Gilbert Ray Cisneros, Jr.DSelf
VCYTVERACYTE, INC.
Purchase
BUY$1,001 – $15KFeb 18, 2026Mar 9, 2026
traded Feb 18, 2026
+19dHOUSE PTR

Evidence

9
MA
McGuire AnnieSVP, General Counsel
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$60K
1,664 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC FORM 4

Evidence

9
MA
McGuire AnnieSVP, General Counsel
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$176K
4,994 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC FORM 4

Evidence

9
LJ
Leite JohnChief Commercial Officer-CLIA
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$185K
5,260 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC FORM 4

Evidence

17
LJ
Leite JohnChief Commercial Officer-CLIA
VCYTVERACYTE, INC.
Grant or award
A—
47.1K sh
Feb 26, 2026Mar 2, 2026
traded Feb 26, 2026
+4dSEC FORM 4

Evidence

15
LJ
Leite JohnChief Commercial Officer-CLIA
VCYTVERACYTE, INC.
Tax withholding
F$345K
8,905 sh
Feb 26, 2026Mar 2, 2026
traded Feb 26, 2026
+4dSEC FORM 4

Evidence

21
MA
McGuire AnnieSVP, General Counsel
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$459K
10.6K sh
Dec 16, 2025Dec 17, 2025
traded Dec 16, 2025
+1dSEC FORM 4

Evidence

11
MA
McGuire AnnieSVP, General Counsel
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$4,368
100 sh
Dec 16, 2025Dec 17, 2025
traded Dec 16, 2025
+1dSEC FORM 4

Evidence

0
MA
McGuire AnnieSVP, General Counsel
VCYTVERACYTE, INC.
Tax withholding · 10b5-1 plan
F$141K
3,052 sh
Dec 2, 2025Dec 4, 2025
traded Dec 2, 2025
+2dSEC FORM 4

Evidence

0
LJ
Leite JohnChief Commercial Officer-CLIA
VCYTVERACYTE, INC.
Tax withholding · 10b5-1 plan
F$134K
2,900 sh
Dec 2, 2025Dec 4, 2025
traded Dec 2, 2025
+2dSEC FORM 4

Evidence

19
LJ
Leite JohnChief Commercial Officer-CLIA
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$61K
1,278 sh
Dec 4, 2025Dec 4, 2025
traded Dec 4, 2025
+0dSEC FORM 4

Evidence

16
MA
McGuire AnnieSVP, General Counsel
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$34K
720 sh
Dec 4, 2025Dec 4, 2025
traded Dec 4, 2025
+0dSEC FORM 4

Evidence

16
MA
McGuire AnnieSVP, General Counsel
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$33K
702 sh
Dec 4, 2025Dec 4, 2025
traded Dec 4, 2025
+0dSEC FORM 4

Evidence

0
CR
Chambers RebeccaChief Financial Officer
VCYTVERACYTE, INC.
Tax withholding · 10b5-1 plan
F$156K
3,384 sh
Dec 2, 2025Dec 4, 2025
traded Dec 2, 2025
+2dSEC FORM 4

Evidence

26
CR
Chambers RebeccaChief Financial Officer
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$398K
8,537 sh
Dec 4, 2025Dec 4, 2025
traded Dec 4, 2025
+0dSEC FORM 4

Evidence

19
CR
Chambers RebeccaChief Financial Officer
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$224K
4,741 sh
Dec 4, 2025Dec 4, 2025
traded Dec 4, 2025
+0dSEC FORM 4

Evidence

12
FG
Febbo Phillip G.Chief Scientific & Med Officer
VCYTVERACYTE, INC.
Tax withholding
F$136K
2,955 sh
Dec 2, 2025Dec 4, 2025
traded Dec 2, 2025
+2dSEC FORM 4

Evidence

23
LJ
Leite JohnChief Commercial Officer-CLIA
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$140K
2,808 sh
Nov 25, 2025Nov 26, 2025
traded Nov 25, 2025
+1dSEC FORM 4

Evidence

23
HJ
Holstein JensDirector
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$61K
1,491 sh
Nov 20, 2025Nov 21, 2025
traded Nov 20, 2025
+1dSEC FORM 4

Evidence

30
HJ
Holstein JensDirector
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$299K
7,049 sh
Nov 20, 2025Nov 21, 2025
traded Nov 20, 2025
+1dSEC FORM 4

Evidence

27
HJ
Holstein JensDirector
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$63K
1,460 sh
Nov 20, 2025Nov 21, 2025
traded Nov 20, 2025
+1dSEC FORM 4

Evidence

20
CR
Chambers RebeccaChief Financial Officer
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$287K
7,000 sh
Nov 5, 2025Nov 7, 2025
traded Nov 5, 2025
+2dSEC FORM 4

Evidence

20
MA
McGuire AnnieSVP, General Counsel
VCYTVERACYTE, INC.
Open-market sale · 10b5-1 plan
SELL$259K
6,466 sh
Nov 5, 2025Nov 7, 2025
traded Nov 5, 2025
+2dSEC FORM 4

Evidence

← Insider ofevidence
Miller Thomas F.
Director · Jun 15, 2026
  • ← Insider ofevidence
    Haas Kevin RichardChief Dev and Tech Officer · Apr 14, 2026
  • ← Disclosed trade inevidence
    Gilbert Ray Cisneros, Jr.Purchase disclosed 2026-03-09 · Mar 9, 2026
  • ← Insider ofevidence
    Febbo Phillip G.Chief Scientific & Med Officer · Dec 4, 2025
  • ← Insider ofevidence
    Leite JohnChief Commercial Officer-CLIA · Nov 26, 2025
  • ← Insider ofevidence
    Holstein JensDirector · Nov 21, 2025
  • ← Insider ofevidence
    Chambers RebeccaChief Financial Officer · Nov 7, 2025
  • ← Insider ofevidence
    McGuire AnnieSVP, General Counsel · Nov 7, 2025